A Modern Approach to Addiction Recovery Marketing

Marketing as Part of the Care-Access Pathway

The most useful reframe for a treatment center CMO right now is to stop treating marketing as a persuasion engine and start treating it as part of the care-access system. The prospective patient, the concerned family member, and the referring clinician are all navigating a clinical decision under time pressure. Every asset the marketing team publishes—search results, service pages, review responses, intake forms, call scripts—either shortens that path to appropriate care or lengthens it.

The evidence base supports this framing. A 2025 systematic review and meta-analysis of remote and digital interventions used alongside alcohol and drug treatment reported 39% lower odds of relapse across 17 interventions when digital tools supplemented in-person care ⁴. The finding measures clinical supplementation, not marketing conversion, but the underlying principle transfers: digital touchpoints matter most when they connect people to the right level of care, not when they simply generate a lead.

That shift changes what a marketing program is accountable for. Qualified admissions volume and cost per admit remain the scoreboard, but the inputs now include claim substantiation, data governance, level-of-care matching, and the quality of the reputation signal a family sees at 11 p.m. on a Tuesday. The 2024–2025 FTC actions against Monument ⁹and Evoke Wellness ^{14, 15}, along with HHS guidance on online tracking technologies ¹², have made this explicit. Substantiation, privacy-safe measurement, and truthful representation are no longer legal overhead sitting next to the growth plan. They are inputs to the growth plan. The rest of this piece works through the operating decisions that follow from that premise.

Demand Sensing Before Channel Planning

Before a CMO allocates another dollar to paid search or a new content sprint, the more consequential question is which demand actually exists in the markets the facility serves, and what those searchers are trying to accomplish. Channel decisions made without that read tend to overfund high-intent branded terms while missing the earlier, higher-volume moments where a facility can shape consideration.

Start with the population behavior. A cross-sectional study of opioid-treatment patients found that 88% had searched online for health or medical information in the prior three months ¹. The sample is narrow—people already engaged in opioid treatment, not the general SUD population or family decision-makers—so the number cannot be generalized to all prospective admits. What it does establish is that the audience adjacent to treatment is already online for health questions, which makes organic discoverability and clinically accurate content a live input to admissions, not a nice-to-have.

Pair that behavioral baseline with query-level demand signals. Research using Google Trends as an infoveillance instrument found that search queries can predict treatment demand spatially and temporally, particularly for opioid-use disorders ⁶. The authors are careful: search volume is an indirect measure influenced by media cycles, terminology drift, and public events, and it should be triangulated with clinical and operational data rather than treated as an admissions proxy. For a CMO, that translates into a specific practice—map query trends against catchment geography, referral patterns, and admissions history before setting content or media weights, and re-run that read quarterly.

Demand sensing also disciplines topic selection. Instead of chasing every high-volume keyword, prioritize the intents that align with the levels of care the facility actually delivers and the payer mix it can serve. A page that ranks for a query the admissions team cannot convert into an appropriate placement is a cost, not an asset.

Evidence-Substantiated Messaging: Separating Clinical Findings from Marketing Claims

The 2024-2025 Enforcement Reality and What Each Case Changes Operationally

The compliance conversation in addiction-treatment marketing changed shape between April 2024 and June 2025. Three actions in particular—Monument, and the two-step FTC pursuit of Evoke Wellness—moved the risk conversation from theoretical HIPAA hygiene to documented enforcement patterns with named practices attached. The R360 civil penalty in 2022 remains the historical foundation for how the FTC treats deceptive addiction-treatment referral conduct ⁸, but the operational instructions for a 2025 marketing program come from what happened next.

The Monument settlement in April 2024 turned on data-sharing practices, not claim language. The FTC alleged that a company promising confidentiality to people seeking alcohol-use-disorder care had disclosed personal health information to advertising platforms; the proposed order banned disclosure of health information for advertising and required affirmative consent before sharing health information with third parties for other purposes ⁹. The operational change is specific. Any privacy or confidentiality promise made on a treatment-center site now needs to match what the site’s tag manager, chat widget, form handler, and remarketing pixels are actually doing. That requires a data inventory tied to the exact wording of the privacy notice, not a separate policy document written by counsel and never reconciled with the marketing stack.

The Evoke Wellness sequence covers the other half of the risk surface: what the ads themselves say and how leads are routed. The FTC filed suit in January 2025 alleging misleading conduct toward consumers seeking substance-use-disorder treatment ¹⁵, and settled in June 2025 for $1.9 million in monetary relief with prohibitions on misrepresenting treatment services, impersonating other businesses, and using rivals’ names in search-engine ads ¹⁴. The FTC’s follow-up business guidance, published the day after the settlement, instructed providers to monitor online profiles for impersonation and framed the Opioid Addiction Recovery Fraud Prevention Act as permitting enhanced remedies, including civil penalties and consumer refunds, for deceptive marketing of substance-use-disorder treatment ¹³.

That sequence changes three specific practices:

1. Competitive search bidding on rival facility names, when combined with ad copy or landing experiences that blur which brand a caller is reaching, is now a documented enforcement theory rather than a gray-area tactic. Ad copy, display URLs, sitelinks, and the landing page’s above-the-fold identity all have to make the operating brand unmistakable.
2. The identity of the entity answering an inbound call has to match the identity implied by the ad; call-routing arrangements that hand leads to a facility the searcher did not select are exposed.
3. Brand-protection monitoring—checking for third parties impersonating the facility in ads, directories, and social profiles—moves from a nice-to-have brand hygiene task into a documented duty the FTC has now flagged in writing ¹³.

For a CMO, the composite instruction is to run three parallel audits, and to keep the artifacts:

• A data-flow audit that reconciles every privacy promise with every tracker firing on the site.
• A claim-and-identity audit of every active search ad, landing page, and call-routing rule.
• A brand-protection audit of paid and organic surfaces for impersonation and lookalike behavior.

Each audit produces a dated file. Substantiation and privacy governance are now defended by what the marketing team can produce on request, not by what it intended.

Privacy-Safe Measurement: Attribution That Survives HHS Tracking Guidance

The measurement stack most treatment centers inherited was built for e-commerce. It assumes that a page view, a form fill, and a purchase can be joined through third-party pixels and shared with ad platforms to optimize bids. Applied to a behavioral-health property, that same stack routinely transmits information the HHS Office for Civil Rights has stated may qualify as protected health information—and the Monument settlement showed the FTC will pursue those disclosures independently of HIPAA status when a privacy promise has been made ⁹.

The HHS guidance is specific about where the exposure lives. Regulated entities must configure tracking technologies so that PHI is only used and disclosed as HIPAA permits, and tracking on authenticated pages, registration flows, and patient portals can involve PHI even when the underlying tool is a general analytics or advertising product ¹². The follow-up implementation document extends the point: the obligation is triggered by what the information collected or disclosed to a third party actually contains, not by the marketing intent behind the tag ¹⁶. A pixel on a page titled with a specific substance, level of care, or facility name, combined with an IP address or device identifier, is the pattern the guidance flags.

That reframes the attribution problem. The question is not “how do we prove which channel drove the call,” it is “what can the measurement system see, store, and share without creating an impermissible disclosure or contradicting the site’s privacy notice.” Three operational moves follow.

First, a data inventory that maps every tag, pixel, chat widget, session-recording script, call-tracking number, and form handler to the exact fields it collects, the third parties it sends data to, and the page contexts where it fires. The inventory is reconciled against the privacy notice line by line—the Monument order required exactly this kind of alignment between confidentiality promises and actual data flows ⁹.

Second, a server-side measurement layer that lets the marketing team keep attribution signal without shipping raw event data from clinically sensitive pages to ad platforms. Conversions can be aggregated, de-identified, and modeled server-side; page-level events on service, condition, and intake URLs are handled differently from events on general brand pages.

Third, a documented consent posture for anything that remains. Where third-party disclosure is retained, it is retained with affirmative consent language that matches what the tag actually does, not a generic cookie banner.

The reporting the CEO sees will look different under this model. Channel attribution becomes modeled rather than deterministic on sensitive pages, and some familiar remarketing audiences disappear. The trade is a measurement stack the legal team can defend on a Monday morning without a forensic rebuild.

Reputation as a Clinical-Quality Signal

Reputation work at a treatment facility is usually assigned to the local SEO calendar and measured in star averages. The peer-reviewed evidence suggests the stakes are higher than that framing implies. A study published in 2024 found that lower online ratings of substance-use-disorder treatment facilities were associated with higher drug-induced mortality at the state level ⁷. The association is ecological—it does not prove that a bad review causes an overdose, and state-level confounding is real—but it is enough to move reputation off the local-SEO checklist and onto the quality dashboard the medical director already reads.

That repositioning changes who owns the work and what gets measured. Review content is patient-experience data that arrives without a survey instrument. A cluster of complaints about intake wait times, discharge planning, or staff turnover is a clinical-operations signal before it is a marketing problem, and routing it only through a marketing response queue wastes the input. The functional model is a shared workflow: marketing owns solicitation cadence, response tone, and platform coverage; clinical and operations own the corrective action when a pattern emerges; both sides see the same monthly report.

Accuracy of the underlying facility record matters as much as the review stream sitting on top of it. Levels of care, licensure, accreditations, insurance accepted, and admissions phone numbers should match across the site, Google Business Profile, directory listings, and payer-facing databases. A family comparing three facilities at midnight is reconciling those fields in real time, and mismatches read as disorganization at exactly the moment trust is being decided.

Continuity Content: Digital Supplements to In-Person Care

The content library at most treatment centers is front-loaded. Landing pages, condition explainers, and admissions FAQs cover the pre-admission window in detail, and then the editorial calendar goes quiet. That gap is a missed clinical opportunity and a missed marketing one. Alumni, families, and referring clinicians all keep searching after admission, and the assets they find—or do not find—shape whether a discharged patient returns to care when a lapse happens.

The evidence for continuity is directional rather than definitive. An earlier systematic review of digital interventions supporting people in recovery found the interventions were generally feasible but not consistently effective at reducing substance use or achieving other recovery goals ³. That should temper the outcome language on any aftercare page. What the more recent literature adds is a framing distinction: digital tools appear to work best when they sit alongside clinical care rather than replace it, which is why the 2025 meta-analysis referenced earlier confined its relapse finding to remote interventions used as supplements ⁴.

For a marketing program, that translates into a specific content lane. Aftercare resources, alumni check-in touchpoints, family education, and relapse-response guidance are published as continuity content, cross-linked to the intake path so a returning searcher reaches a human quickly. Claims stay modest, sources stay attached, and the assets are measured on re-engagement and re-admission volume rather than session time. That closes the loop the admissions funnel opens.

A Note for Multi-Facility Operators

The preceding sections address a single-facility CMO. Operators running a portfolio of programs across multiple states carry the same obligations, multiplied by every brand, license, and landing page in the group. Two portfolio-specific issues deserve explicit attention. First, the identity representation rules the FTC applied in the Evoke Wellness settlement ¹⁴cut against shared call centers that route inbound calls across sister facilities without making the receiving brand clear before the caller commits. Second, the data-flow reconciliation the Monument order required ⁹has to be run per property, because a single misconfigured pixel on one facility site can implicate the parent entity. Portfolio governance means one claim library, one data inventory template, one review workflow, and per-brand artifacts stored under each facility’s name.